This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00298/identifier/pubchem-compound/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00298/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00298/identifier/drugbank/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n5http://linked.opendata.cz/resource/drugbank/drug/DB00298/identifier/chemspider/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/drug/DB00298/identifier/chebi/
owlhttp://www.w3.org/2002/07/owl#
n6http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00298/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00298/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00298
rdf:type
n6:Drug
n6:description
Dapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination. [Wikipedia]
n6:group
approved
n6:indication
Used in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations.
n6:manufacturer
n11:271B4DD6-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00298 n18:DB00298
dcterms:title
Dapiprazole
adms:identifier
n4:51066 n5:2298190 n16:Dapiprazole n17:PA164749109 n19:3033538 n20:46508859 n21:DB00298
n6:mechanismOfAction
Dapiprazole acts through blocking the alpha1-adrenergic receptors in smooth muscle. It produces miosis through an effect on the dilator muscle of the iris and does not have any significant activity on ciliary muscle contraction and, therefore does not induce a significant change in the anterior chamber depth or the thickness of the lens.
n6:packager
n11:271B4DD5-363D-11E5-9242-09173F13E4C5
n6:synonym
Dapiprazol Dapiprazolum 5,6,7,8-Tetrahydro-3-(2-(4-(O-tolyl)-1-piperazinyl)ethyl)-S-triazolo(4,3-a)pyridine
n6:toxicity
Oral LD<sub>50</sub> is 1189-2100 mg/kg in mice, rats and rabbits.
foaf:page
n13:dapiprazole.html
n6:IUPAC-Name
n7:271B4DDB-363D-11E5-9242-09173F13E4C5
n6:InChI
n7:271B4DE1-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula
n7:271B4DE0-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n7:271B4DDD-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight
n7:271B4DDE-363D-11E5-9242-09173F13E4C5
n6:SMILES
n7:271B4DDF-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility
n7:271B4DD9-363D-11E5-9242-09173F13E4C5 n7:271B4DF0-363D-11E5-9242-09173F13E4C5
n6:logP
n7:271B4DDA-363D-11E5-9242-09173F13E4C5 n7:271B4DD7-363D-11E5-9242-09173F13E4C5 n7:271B4DF1-363D-11E5-9242-09173F13E4C5
n6:logS
n7:271B4DD8-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:S01EX02
n6:H-Bond-Acceptor-Count
n7:271B4DE7-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count
n7:271B4DE8-363D-11E5-9242-09173F13E4C5
n6:InChIKey
n7:271B4DE2-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-
n7:271B4DE3-363D-11E5-9242-09173F13E4C5
n6:Polarizability
n7:271B4DE5-363D-11E5-9242-09173F13E4C5
n6:Refractivity
n7:271B4DE4-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count
n7:271B4DE6-363D-11E5-9242-09173F13E4C5
n6:absorption
Systemic absorption is negligible.
n6:affectedOrganism
Humans and other mammals
n6:casRegistryNumber
72822-12-9
n6:category
n6:Bioavailability
n7:271B4DEC-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter
n7:271B4DEE-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule
n7:271B4DEF-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings
n7:271B4DEB-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge
n7:271B4DEA-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five
n7:271B4DED-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name
n7:271B4DDC-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-
n7:271B4DE9-363D-11E5-9242-09173F13E4C5